BioSpace News Archive

BD, a leading global medical technology company, provided an update on two voluntary recalls related to certain Alaris™ Pump Modules Model 8100 manufactured between April 2011 and June 2017 and certain model codes and lot numbers of the Alaris™ Pump Infusion Sets used with the Alaris™ Pump Model 8100.

LifeMax Laboratories, Inc. announced that the Food & Drug Administration granted rare pediatric disease designation to LM-030, an investigational therapy licensed from Novartis and ready to enter into pivotal clinical trials for the treatment of Netherton Syndrome.

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology

Unites Four of the Top US Clinical Research Facilities to Reduce Time and Cost for New Drug Development

Quotient Sciences and global investment firm Permira announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in Quotient from companies controlled by GHO Capital and other investors for an undisclosed sum.

Company’s Intelligent Sensor Extends Metrics for Evaluating Automotive LiDAR System Performance

VolitionRx Limited has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. to help introduce the Nu.Q platform to China.

OncoCell MDx also recently announced the appointments of Mark McDonough as President and CEO and Christopher Thibodeau as Chief Operating Officer.

Fifteen abstracts, along with community-focused symposia and workshops, reflect Gilead’s ongoing commitment to scientific innovation, a key pillar to addressing unmet and evolving medical needs in HIV.

The Company intends to announce the results of required follow-up to the chronic procedures by the end of August.